Literature DB >> 26692333

Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling.

Fernando G Osorio1, Clara Soria-Valles1, Olaya Santiago-Fernández1, Teresa Bernal1,2, María Mittelbrunn1,3,4, Enrique Colado2, Francisco Rodríguez1, Elena Bonzon-Kulichenko5, Jesús Vázquez5, Montserrat Porta-de-la-Riva6,7, Julián Cerón6, Antonio Fueyo8, Juan Li9,10, Anthony R Green9,10,11, José M P Freije1, Carlos López-Otín1.   

Abstract

AIRAPL (arsenite-inducible RNA-associated protein-like) is an evolutionarily conserved regulator of cellular proteostasis linked to longevity in nematodes, but its biological function in mammals is unknown. We show herein that AIRAPL-deficient mice develop a fully-penetrant myeloproliferative neoplastic process. Proteomic analysis of AIRAPL-deficient mice revealed that this protein exerts its antineoplastic function through the regulation of the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway. We demonstrate that AIRAPL interacts with newly synthesized insulin-related growth factor-1 receptor (IGF1R) polypeptides, promoting their ubiquitination and proteasome-mediated degradation. Accordingly, genetic and pharmacological IGF1R inhibitory strategies prevent the hematological disease found in AIRAPL-deficient mice as well as that in mice carrying the Jak2(V617F) mutation, thereby demonstrating the causal involvement of this pathway in the pathogenesis of myeloproliferative neoplasms. Consistent with its proposed role as a tumor suppressor of myeloid transformation, AIRAPL expression is widely abrogated in human myeloproliferative disorders. Collectively, these findings support the oncogenic relevance of proteostasis deregulation in hematopoietic cells, and they unveil novel therapeutic targets for these frequent hematological neoplasias.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26692333     DOI: 10.1038/nm.4013

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  49 in total

Review 1.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

2.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

3.  Basic Caenorhabditis elegans methods: synchronization and observation.

Authors:  Montserrat Porta-de-la-Riva; Laura Fontrodona; Alberto Villanueva; Julián Cerón
Journal:  J Vis Exp       Date:  2012-06-10       Impact factor: 1.355

4.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

5.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Authors:  Ann Mullally; Claudia Bruedigam; Luke Poveromo; Florian H Heidel; Amy Purdon; Therese Vu; Rebecca Austin; Dirk Heckl; Lawrence J Breyfogle; Catherine Paine Kuhn; Demetrios Kalaitzidis; Scott A Armstrong; David A Williams; Geoff R Hill; Benjamin L Ebert; Steven W Lane
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

6.  A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment.

Authors:  Agnieszka Rybak; Heiko Fuchs; Lena Smirnova; Christine Brandt; Elena E Pohl; Robert Nitsch; F Gregory Wulczyn
Journal:  Nat Cell Biol       Date:  2008-07-06       Impact factor: 28.824

7.  JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.

Authors:  Juan Li; Dominik Spensberger; Jong Sook Ahn; Shubha Anand; Philip A Beer; Cedric Ghevaert; Edwin Chen; Ariel Forrai; Linda M Scott; Rita Ferreira; Peter J Campbell; Steve P Watson; Pentao Liu; Wendy N Erber; Brian J P Huntly; Katrin Ottersbach; Anthony R Green
Journal:  Blood       Date:  2010-05-20       Impact factor: 22.113

8.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

9.  Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Authors:  Christine M Lovly; Nerina T McDonald; Heidi Chen; Sandra Ortiz-Cuaran; Lukas C Heukamp; Yingjun Yan; Alexandra Florin; Luka Ozretić; Diana Lim; Lu Wang; Zhao Chen; Xi Chen; Pengcheng Lu; Paul K Paik; Ronglai Shen; Hailing Jin; Reinhard Buettner; Sascha Ansén; Sven Perner; Michael Brockmann; Marc Bos; Jürgen Wolf; Masyar Gardizi; Gavin M Wright; Benjamin Solomon; Prudence A Russell; Toni-Maree Rogers; Yoshiyuki Suehara; Monica Red-Brewer; Rudy Tieu; Elisa de Stanchina; Qingguo Wang; Zhongming Zhao; David H Johnson; Leora Horn; Kwok-Kin Wong; Roman K Thomas; Marc Ladanyi; William Pao
Journal:  Nat Med       Date:  2014-08-31       Impact factor: 53.440

10.  JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

Authors:  Juan Li; David G Kent; Anna L Godfrey; Harriet Manning; Jyoti Nangalia; Athar Aziz; Edwin Chen; Kourosh Saeb-Parsy; Juergen Fink; Rachel Sneade; Tina L Hamilton; Dean C Pask; Yvonne Silber; Xiaodong Zhao; Cedric Ghevaert; Pentao Liu; Anthony R Green
Journal:  Blood       Date:  2014-04-01       Impact factor: 22.113

View more
  16 in total

1.  Targeting a regulator of protein homeostasis in myeloproliferative neoplasms.

Authors:  Lindsay M LaFave; Ross L Levine
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

2.  Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia.

Authors:  Gabriel Bretones; Miguel G Álvarez; Javier R Arango; David Rodríguez; Ferran Nadeu; Miguel A Prado; Rafael Valdés-Mas; Diana A Puente; Joao A Paulo; Julio Delgado; Neus Villamor; Armando López-Guillermo; Daniel J Finley; Steven P Gygi; Elías Campo; Víctor Quesada; Carlos López-Otín
Journal:  Blood       Date:  2018-09-04       Impact factor: 22.113

3.  Loss of the deubiquitinase USP36 destabilizes the RNA helicase DHX33 and causes preimplantation lethality in mice.

Authors:  Julia M Fraile; Diana Campos-Iglesias; Francisco Rodríguez; Aurora Astudillo; Roser Vilarrasa-Blasi; Nuria Verdaguer-Dot; Miguel A Prado; Joao A Paulo; Steven P Gygi; José I Martín-Subero; José M P Freije; Carlos López-Otín
Journal:  J Biol Chem       Date:  2017-12-22       Impact factor: 5.157

4.  The novel tumor suppressor AIRAPL regulates IGF1R proteostasis.

Authors:  Fernando G Osorio; José M P Freije; Carlos López-Otín
Journal:  Cell Cycle       Date:  2016-02-22       Impact factor: 4.534

5.  NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells.

Authors:  Bruna Alves Fenerich; Jaqueline Cristina Fernandes; Ana Paula Nunes Rodrigues Alves; Juan Luiz Coelho-Silva; Renata Scopim-Ribeiro; Priscila Santos Scheucher; Christopher A Eide; Cristina E Tognon; Brian J Druker; Eduardo Magalhães Rego; João Agostinho Machado-Neto; Fabiola Traina
Journal:  Signal Transduct Target Ther       Date:  2020-01-24

6.  FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion.

Authors:  Joanna Stanicka; Leonie Rieger; Sandra O'Shea; Orla Cox; Michael Coleman; Ciara O'Flanagan; Barbara Addario; Nuala McCabe; Richard Kennedy; Rosemary O'Connor
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

Review 7.  A Mighty "Protein Extractor" of the Cell: Structure and Function of the p97/CDC48 ATPase.

Authors:  Yihong Ye; Wai Kwan Tang; Ting Zhang; Di Xia
Journal:  Front Mol Biosci       Date:  2017-06-13

8.  IGF1R deficiency attenuates acute inflammatory response in a bleomycin-induced lung injury mouse model.

Authors:  Sergio Piñeiro-Hermida; Icíar P López; Elvira Alfaro-Arnedo; Raquel Torrens; María Iñiguez; Lydia Alvarez-Erviti; Carlos Ruíz-Martínez; José G Pichel
Journal:  Sci Rep       Date:  2017-06-27       Impact factor: 4.379

9.  Hypoxic TAM-derived exosomal miR-155-5p promotes RCC progression through HuR-dependent IGF1R/AKT/PI3K pathway.

Authors:  Wenyu Gu; Linjing Gong; Xu Wu; Xudong Yao
Journal:  Cell Death Discov       Date:  2021-06-15

Review 10.  Type I insulin-like growth factor receptor signaling in hematological malignancies.

Authors:  Deeksha Vishwamitra; Suraj Konnath George; Ping Shi; Ahmed O Kaseb; Hesham M Amin
Journal:  Oncotarget       Date:  2017-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.